Argus Research raises price targets for Eli Lilly and Hilton
Argus Research lifted its price target on Eli Lilly to $1550 and on Hilton to $410 a share, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Argus Research analysts raised their price target on Eli Lilly to $1550 a share from $1300. For Hilton, the target rose to $410 a share from $400, and the analysts kept their Buy rating. Dow Jones Newswires reported the actions, citing Benzinga. The original material contains only links to ratings pages, with no further commentary from the analysts.
why it matters
Price target changes are a routine part of market coverage. They reflect analysts' valuation views rather than company guidance, and they usually have a limited effect on share prices. Investors typically focus more on earnings reports and updated company forecasts.
tags
instruments
sources
- Eli Lilly Price Target Raised to $1550.00/Share From $1300.00 by Argus Research — Dow Jones Newswires, 30 October 2026 at 14:01 UTC
- Hilton Price Target Raised to $410.00/Share From $400.00 by Argus Research — Dow Jones Newswires, 30 October 2026 at 14:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗